<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jcr Pharmaceuticals Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd</link>
<description>Latest news and press releases for Jcr Pharmaceuticals Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 05 Feb 2026 00:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jcr-pharmaceuticals-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d621a4beedb30cb6fc2d22.webp</url>
<title>Jcr Pharmaceuticals Co., Ltd.</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd</link>
</image>
<item>
<title>JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-research-presentations-at-worldsymposiumtm-2026-showcase-data-from-its-investigational-treatments-for-lysosomal-storage-disorders</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-research-presentations-at-worldsymposiumtm-2026-showcase-data-from-its-investigational-treatments-for-lysosomal-storage-disorders</guid>
<pubDate>Thu, 05 Feb 2026 00:30:00 GMT</pubDate>
<description>HYOGO, Japan, February 05, 2026--JCR announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies at the WORLDSymposium 2026.</description>
</item>
<item>
<title>JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-22nd-annual-worldsymposiumtm-2026</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-22nd-annual-worldsymposiumtm-2026</guid>
<pubDate>Tue, 27 Jan 2026 15:55:00 GMT</pubDate>
<description>HYOGO, Japan, January 27, 2026--JCR Pharmaceuticals announced that it will present data at the 22nd Annual WORLDSymposium 2026, held February 2-6, 2026, in San Diego, Calif.</description>
</item>
<item>
<title>JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>HYOGO, Japan, January 08, 2026--JCR Pharmaceuticals announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12–15, 2026.</description>
</item>
<item>
<title>Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/italfarmaco-and-jcr-pharmaceuticals-announce-commercialisation-agreement-for-givinostat-in-japan-and-strategic-collaboration-in-rare-disease</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/italfarmaco-and-jcr-pharmaceuticals-announce-commercialisation-agreement-for-givinostat-in-japan-and-strategic-collaboration-in-rare-disease</guid>
<pubDate>Wed, 24 Dec 2025 10:00:00 GMT</pubDate>
<description>MILAN & HYOGO, Japan, December 24, 2025--JCR Pharmaceuticals and Italfarmaco announced an exclusive licensing agreement for the development and commercialization of givinostat in Japan.</description>
</item>
<item>
<title>JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-enhances-delivery-of-aav-gene-therapy-to-central-nervous-system-and-muscle-with-novel-capsid-engineering-platform-technology</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-enhances-delivery-of-aav-gene-therapy-to-central-nervous-system-and-muscle-with-novel-capsid-engineering-platform-technology</guid>
<pubDate>Tue, 07 Oct 2025 16:30:00 GMT</pubDate>
<description>HYOGO, Japan, October 07, 2025--JCR presented non-clinical data that demonstrate the ability of its proprietary JUST-AAV platform to achieve efficient delivery of AAV gene therapy.</description>
</item>
<item>
<title>JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-licensing-agreement-with-menagen-to-commercialize-agalsidase-beta-bs-iv-infusion-jcr-across-nine-menat-markets</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-licensing-agreement-with-menagen-to-commercialize-agalsidase-beta-bs-iv-infusion-jcr-across-nine-menat-markets</guid>
<pubDate>Wed, 01 Oct 2025 17:13:00 GMT</pubDate>
<description>HYOGO, Japan, October 01, 2025--JCR announced an exclusive licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets.</description>
</item>
<item>
<title>JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-european-society-of-gene-and-cell-therapy-esgct-32nd-annual-congress</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-european-society-of-gene-and-cell-therapy-esgct-32nd-annual-congress</guid>
<pubDate>Tue, 30 Sep 2025 17:11:00 GMT</pubDate>
<description>HYOGO, Japan, September 30, 2025--JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT 32nd Annual Congress.</description>
</item>
<item>
<title>Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-ministry-of-health-labour-and-welfare-of-japan</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-ministry-of-health-labour-and-welfare-of-japan</guid>
<pubDate>Mon, 29 Sep 2025 16:33:00 GMT</pubDate>
<description>TOKYO & HYOGO, Japan, September 29, 2025--JCR and MEDIPAL announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446 for MPS IIIB.</description>
</item>
<item>
<title>JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-and-alexion-achieve-milestone-in-collaborative-neurodegenerative-disease-program</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-and-alexion-achieve-milestone-in-collaborative-neurodegenerative-disease-program</guid>
<pubDate>Fri, 19 Sep 2025 14:53:00 GMT</pubDate>
<description>HYOGO, Japan, September 19, 2025--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease.</description>
</item>
<item>
<title>JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-celebrates-its-50th-anniversary-of-advancing-science-and-changing-lives</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-celebrates-its-50th-anniversary-of-advancing-science-and-changing-lives</guid>
<pubDate>Fri, 12 Sep 2025 15:23:00 GMT</pubDate>
<description>HYOGO, Japan, September 12, 2025--JCR Pharmaceuticals today announced that it will celebrate its 50th anniversary on September 13, 2025, marking five decades of advancing science.</description>
</item>
<item>
<title>JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-presents-long-term-clinical-data-on-pabinafusp-alfa-for-the-treatment-of-mucopolysaccharidosis-type-ii-mps-ii-at-iciem-2025</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-presents-long-term-clinical-data-on-pabinafusp-alfa-for-the-treatment-of-mucopolysaccharidosis-type-ii-mps-ii-at-iciem-2025</guid>
<pubDate>Mon, 08 Sep 2025 17:03:00 GMT</pubDate>
<description>HYOGO, Japan, September 08, 2025--JCR announced that it presented new data from its pipeline of brain-penetrant enzyme replacement therapies at the 15th ICIEM 2025.</description>
</item>
<item>
<title>MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/medipal-holdings-and-jcr-pharmaceuticals-sign-global-licensing-and-japan-co-development-agreement-for-jr-479-a-novel-therapy-for-gm2-gangliosidosis</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/medipal-holdings-and-jcr-pharmaceuticals-sign-global-licensing-and-japan-co-development-agreement-for-jr-479-a-novel-therapy-for-gm2-gangliosidosis</guid>
<pubDate>Tue, 02 Sep 2025 16:31:00 GMT</pubDate>
<description>TOKYO & HYOGO, Japan, September 02, 2025--JCR and MEDIPAL announced an exclusive global licensing deal and a co-development and commercialization partnership in Japan for JR-479.</description>
</item>
<item>
<title>JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-15th-international-congress-of-inborn-errors-of-metabolism-iciem-2025</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-to-present-at-the-15th-international-congress-of-inborn-errors-of-metabolism-iciem-2025</guid>
<pubDate>Thu, 28 Aug 2025 11:30:00 GMT</pubDate>
<description>HYOGO, Japan, August 28, 2025--JCR Pharmaceuticals announced that it will present data at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025 next week.</description>
</item>
<item>
<title>JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-selected-for-japans-regenerative-medicine-cdmo-subsidy-program</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-selected-for-japans-regenerative-medicine-cdmo-subsidy-program</guid>
<pubDate>Wed, 16 Jul 2025 15:36:00 GMT</pubDate>
<description>HYOGO, Japan, July 16, 2025--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been selected for the Ministry of Economy, Trade and Industry’s "Regenerative CDMO Subsidy" as of July 15, 2025. The subsidy will support facility upgrades and equipment installation to expand biomanufacturing capacity for regenerative, cell, and gene therapies.</description>
</item>
<item>
<title>JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-and-acumen-pharmaceuticals-announce-collaboration-to-develop-therapy-for-alzheimers-disease-enabled-by-j-brain-cargor-technology-platform</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-and-acumen-pharmaceuticals-announce-collaboration-to-develop-therapy-for-alzheimers-disease-enabled-by-j-brain-cargor-technology-platform</guid>
<pubDate>Tue, 15 Jul 2025 11:00:00 GMT</pubDate>
<description>HYOGO, Japan, July 15, 2025--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced a joint collaboration, option and license agreement with Acumen Pharmaceuticals to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®.</description>
</item>
<item>
<title>JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-enters-license-agreement-with-alexion-for-proprietary-just-aav-capsids-to-be-used-in-the-development-of-genomic-medicines</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-enters-license-agreement-with-alexion-for-proprietary-just-aav-capsids-to-be-used-in-the-development-of-genomic-medicines</guid>
<pubDate>Tue, 08 Jul 2025 17:58:00 GMT</pubDate>
<description>HYOGO, Japan, July 08, 2025--JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to develop genomic medicines.</description>
</item>
<item>
<title>JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-the-achievement-of-enrollment-in-the-jr-141-global-phase-iii-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-the-achievement-of-enrollment-in-the-jr-141-global-phase-iii-clinical-trial</guid>
<pubDate>Wed, 02 Jul 2025 15:12:00 GMT</pubDate>
<description>HYOGO, Japan, July 02, 2025--JCR today announced that it achieved the enrollment of the target number of participants in the global Phase III clinical trial of JR-141.</description>
</item>
<item>
<title>Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-european-commission-ec</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/notice-of-orphan-drug-designation-for-jr-446-for-mucopolysaccharidosis-type-iiib-by-european-commission-ec</guid>
<pubDate>Tue, 24 Jun 2025 16:38:00 GMT</pubDate>
<description>TOKYO & HYOGO, Japan, June 24, 2025--JCR and MEDIPAL announced that the EC has granted ODD to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB.</description>
</item>
<item>
<title>JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-launch-of-mucopolysaccharidosis-mps-type-ii-disease-awareness-film-featured-in-the-next-frontier-series</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-announces-launch-of-mucopolysaccharidosis-mps-type-ii-disease-awareness-film-featured-in-the-next-frontier-series</guid>
<pubDate>Wed, 18 Jun 2025 17:29:00 GMT</pubDate>
<description>HYOGO, Japan, June 18, 2025--JCR announced the launch of a film featured in The Next Frontier, a series presented by BIO and produced by BBC StoryWorks Commercial Productions.</description>
</item>
<item>
<title>JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website</title>
<link>https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-marks-50-years-of-innovation-with-launch-of-one-of-a-kind-global-website</link>
<guid isPermaLink="true">https://6ix.com/company/jcr-pharmaceuticals-co-ltd/news/jcr-pharmaceuticals-marks-50-years-of-innovation-with-launch-of-one-of-a-kind-global-website</guid>
<pubDate>Fri, 06 Jun 2025 16:27:00 GMT</pubDate>
<description>HYOGO, Japan, June 06, 2025--JCR Pharmaceuticals announced the launch of its new global website, as the company celebrates its 50th anniversary.</description>
</item>
</channel>
</rss>